U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H15F3N4O4
Molecular Weight 408.3313
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CONTEZOLID

SMILES

FC1=C(N2CCC(=O)C=C2)C(F)=C(F)C(=C1)N3C[C@H](CNC4=NOC=C4)OC3=O

InChI

InChIKey=SULYVXZZUMRQAX-NSHDSACASA-N
InChI=1S/C18H15F3N4O4/c19-12-7-13(15(20)16(21)17(12)24-4-1-10(26)2-5-24)25-9-11(29-18(25)27)8-22-14-3-6-28-23-14/h1,3-4,6-7,11H,2,5,8-9H2,(H,22,23)/t11-/m0/s1

HIDE SMILES / InChI

Molecular Formula C18H15F3N4O4
Molecular Weight 408.3313
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

MRX-I is a potent oxazolidinone antibiotic against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, penicillin-intermediate S. pneumoniae, and vancomycin-resistant enterococci. MRX-I demonstrated comparable or slightly higher activity than linezolid and was active against enterococci resistant to both vancomycin and teicoplanin. In addition, MRX-I exhibited bactericidal activities against staphylococci and streptococci but was bacteriostatic against enterococci. MRX-I inhibits formation of functional 70S initiation complex essential for bacterial protein synthesis, leading to the cessation of bacterial growth. Oral MRX-I was associated with a greater bioavailability and exposure when administered with food, and minimal accumulation of MRX-I occurred after multiple-dose administration. Oral MRX-I was well tolerated at single doses of up to 1,200 and 800 mg q12h for up to 28 days; all adverse events were mild to moderate in severity, and there was no drug discontinuation due to adverse events.

Approval Year

PubMed

PubMed

TitleDatePubMed
Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.
2018 Feb
Patents

Sample Use Guides

800 mg every 12 h (q12h) for 28 days
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:48:13 GMT 2023
Edited
by admin
on Sat Dec 16 09:48:13 GMT 2023
Record UNII
B669M62ELP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CONTEZOLID
USAN   INN  
Official Name English
4(1H)-PYRIDINONE, 2,3-DIHYDRO-1-(2,3,6-TRIFLUORO-4-((5S)-5-((3-ISOXAZOLYLAMINO)METHYL)-2-OXO-3-OXAZOLIDINYL)PHENYL)-
Systematic Name English
CONTEZOLID [USAN]
Common Name English
MRX-I
Code English
contezolid [INN]
Common Name English
Contezolid [WHO-DD]
Common Name English
1-(2,3,6-Trifluoro-4-{(5S)-5-[(1,2-oxazol-3-ylamino)methyl]-2-oxo-1,3-oxazolidin-3-yl}phenyl)-2,3-dihydropyridin-4(1H)-one
Systematic Name English
Code System Code Type Description
DRUG BANK
DB12796
Created by admin on Sat Dec 16 09:48:13 GMT 2023 , Edited by admin on Sat Dec 16 09:48:13 GMT 2023
PRIMARY
FDA UNII
B669M62ELP
Created by admin on Sat Dec 16 09:48:13 GMT 2023 , Edited by admin on Sat Dec 16 09:48:13 GMT 2023
PRIMARY
NCI_THESAURUS
C171693
Created by admin on Sat Dec 16 09:48:13 GMT 2023 , Edited by admin on Sat Dec 16 09:48:13 GMT 2023
PRIMARY
INN
10775
Created by admin on Sat Dec 16 09:48:13 GMT 2023 , Edited by admin on Sat Dec 16 09:48:13 GMT 2023
PRIMARY
CAS
1112968-42-9
Created by admin on Sat Dec 16 09:48:13 GMT 2023 , Edited by admin on Sat Dec 16 09:48:13 GMT 2023
PRIMARY
USAN
EF-72
Created by admin on Sat Dec 16 09:48:13 GMT 2023 , Edited by admin on Sat Dec 16 09:48:13 GMT 2023
PRIMARY
PUBCHEM
25184541
Created by admin on Sat Dec 16 09:48:13 GMT 2023 , Edited by admin on Sat Dec 16 09:48:13 GMT 2023
PRIMARY
SMS_ID
100000181104
Created by admin on Sat Dec 16 09:48:13 GMT 2023 , Edited by admin on Sat Dec 16 09:48:13 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
MAJOR
PLASMA; URINE
METABOLITE -> PARENT
FECAL; PLASMA; URINE
PRODRUG -> METABOLITE ACTIVE
METABOLITE -> PARENT
MAJOR
PLASMA; URINE
METABOLITE -> PARENT
FECAL; PLASMA; URINE
METABOLITE -> PARENT
FECAL; PLASMA; URINE
METABOLITE -> PARENT
FECAL
METABOLITE -> PARENT
FECAL; PLASMA; URINE
METABOLITE -> PARENT
FECAL; PLASMA; URINE
Related Record Type Details
ACTIVE MOIETY